Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Cash & Equivalents: 2016-2025

Historic Cash & Equivalents for Rhythm Pharmaceuticals (RYTM) over the last 9 years, with Sep 2025 value amounting to $416.1 million.

  • Rhythm Pharmaceuticals' Cash & Equivalents rose 767.18% to $416.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $416.1 million, marking a year-over-year increase of 767.18%. This contributed to the annual value of $89.6 million for FY2024, which is 48.32% up from last year.
  • According to the latest figures from Q3 2025, Rhythm Pharmaceuticals' Cash & Equivalents is $416.1 million, which was up 42.99% from $291.0 million recorded in Q2 2025.
  • Rhythm Pharmaceuticals' Cash & Equivalents' 5-year high stood at $416.1 million during Q3 2025, with a 5-year trough of $48.0 million in Q3 2024.
  • Moreover, its 3-year median value for Cash & Equivalents was $110.0 million (2023), whereas its average is $157.0 million.
  • In the last 5 years, Rhythm Pharmaceuticals' Cash & Equivalents tumbled by 64.99% in 2023 and then soared by 767.18% in 2025.
  • Rhythm Pharmaceuticals' Cash & Equivalents (Quarterly) stood at $59.6 million in 2021, then surged by 114.86% to $128.0 million in 2022, then tumbled by 52.81% to $60.4 million in 2023, then soared by 48.32% to $89.6 million in 2024, then skyrocketed by 767.18% to $416.1 million in 2025.
  • Its Cash & Equivalents was $416.1 million in Q3 2025, compared to $291.0 million in Q2 2025 and $314.5 million in Q1 2025.